Emerging Anticoagulant Drugs
Open Access
- 1 September 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (9) , 1491-1500
- https://doi.org/10.1161/01.atv.0000084827.77945.66
Abstract
—The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing.Keywords
This publication has 88 references indexed in Scilit:
- Ximelagatran versus warfarin forstroke prevention in patientswith nonvalvular atrial fibrillation: SPORTIF ii: a dose-guiding, tolerability, and safety studyJournal of the American College of Cardiology, 2003
- Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin InhibitorClinical Pharmacokinetics, 2003
- Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trialThe Lancet, 1999
- Deep-vein thrombosisThe Lancet, 1999
- Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopeniaBlood Coagulation & Fibrinolysis, 1997
- ArgatrobanCoronary Artery Disease, 1996
- Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplastyAmerican Heart Journal, 1995
- The Pathogenesis of Coronary Artery Disease and the Acute Coronary SyndromesNew England Journal of Medicine, 1992
- The Structure of a Complex of Recombinant Hirudin and Human α-ThrombinScience, 1990
- The effect of substituting phosphotyrosine for sulphotyrosine on the activity of hirudinEuropean Journal of Biochemistry, 1990